Fabrication of H2O2-driven nanoreactors for innovative cancer treatments

Nanoscale ◽  
2019 ◽  
Vol 11 (35) ◽  
pp. 16164-16186 ◽  
Author(s):  
Ziliang Dong ◽  
Zhijuan Yang ◽  
Yu Hao ◽  
Liangzhu Feng
Keyword(s):  
Oxidative Stress ◽  
Cancer Treatment ◽  
Tumour Hypoxia ◽  
Cancer Treatments

Innovative H2O2-driven nanoreactors have been designed and attempted for effective cancer treatment via amplifying intratumoural oxidative stress or attenuating tumour hypoxia.

scholarly journals The Two Sides of Dietary Antioxidants in Cancer Therapy

2020 ◽  
Author(s):  
Musbau Adewumi Akanji ◽  
Heritage Demilade Fatinukun ◽  
Damilare Emmanuel Rotimi ◽  
Boluwatife Lawrence Afolabi ◽  
Oluyomi Stephen Adeyemi
Keyword(s):  
Oxidative Stress ◽  
Side Effects ◽  
Cancer Therapy ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Dietary Antioxidants ◽  
Cancer Treatments ◽  
The World ◽  
Two Sides ◽  
Radiotherapy Treatment

Cancer is a major cause of mortality around the world, representing about 13% of deaths on the planet. Among the available cancer treatments, chemotherapy is most frequently utilized compared to other treatments such as surgery and radiotherapy. Many dietary antioxidants have proven to effectively prevent oxidative stress, which has been noted in many disease pathogeneses, including cancer. However, during chemotherapy or radiotherapy treatment of cancer patients, antioxidants are used as an adjuvant treatment. The use of a proof-based technique is advised in determining the supplements most suited to cancer patients. Though there are numerous opinions about the dangers and advantages of antioxidants, it is reasonable to conclude that side effects caused by antioxidants, for now, remain unclear for patients during cancer treatment, aside from smokers during radiotherapy. In this report, details of the effectiveness of antioxidants on cancer treatment aiding in the reduction of cancer therapy side effects are discussed.

scholarly journals Prolonged SARS-CoV-2-RNA Detection from Nasopharyngeal Swabs in an Oncologic Patient: What Impact on Cancer Treatment?

2021 ◽  
Vol 28 (1) ◽  
pp. 847-852
Author(s):  
Anna Ferrari ◽  
Marco Trevenzoli ◽  
Lolita Sasset ◽  
Elisabetta Di Liso ◽  
Toni Tavian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Clinical Symptoms ◽  
Palliative Radiotherapy ◽  
Rt Pcr ◽  
Cancer Treatments ◽  
Global Challenge ◽  
Viral Culture ◽  
Pcr Assays

The pandemic of SARS-CoV-2 is a serious global challenge affecting millions of people worldwide. Cancer patients are at risk for infection exposure and serious complications. A prompt diagnosis of SARS-CoV-2 infection is crucial for the timely adoption of isolation measures and the appropriate management of cancer treatments. In lung cancer patients the symptoms of infection 19 may resemble those exhibited by the underlying oncologic condition, possibly leading to diagnostic overlap and delays. Moreover, cancer patients might display a prolonged positivity of nasopharyngeal RT-PCR assays for SARS-CoV-2, causing long interruptions or delay of cancer treatments. However, the association between the positivity of RT-PCR assays and the patient’s infectivity remains uncertain. We describe the case of a patient with non-small cell lung cancer, and a severe ab extrinseco compression of the trachea, whose palliative radiotherapy was delayed because of the prolonged positivity of nasopharyngeal swabs for SARS-CoV-2. The patient did not show clinical symptoms suggestive of active infection, but the persistent positivity of RT-PCR assays imposed the continuation of isolation measures and the delay of radiotherapy for over two months. Finally, the negative result of SARS-CoV-2 viral culture allowed us to verify the absence of viral activity and to rule out the infectivity of the patient, who could finally continue her cancer treatment.

scholarly journals Recent Advances of Nanotechnology-Facilitated Bacteria-Based Drug and Gene Delivery Systems for Cancer Treatment

Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 940
Author(s):  
Chaojie Zhu ◽  
Zhiheng Ji ◽  
Junkai Ma ◽  
Zhijie Ding ◽  
Jie Shen ◽  
...  
Keyword(s):  
Gene Delivery ◽  
Cancer Treatment ◽  
Delivery Systems ◽  
Cancer Targeting ◽  
Cancer Treatments ◽  
Recent Advances ◽  
Therapeutic Mechanisms ◽  
Bacterial Therapy ◽  
Targeting Ability ◽  
Drug And Gene Delivery

Cancer is one of the most devastating and ubiquitous human diseases. Conventional therapies like chemotherapy and radiotherapy are the most widely used cancer treatments. Despite the notable therapeutic improvements that these measures achieve, disappointing therapeutic outcome and cancer reoccurrence commonly following these therapies demonstrate the need for better alternatives. Among them, bacterial therapy has proven to be effective in its intrinsic cancer targeting ability and various therapeutic mechanisms that can be further bolstered by nanotechnology. In this review, we will discuss recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems in cancer treatment. Therapeutic mechanisms of these hybrid nanoformulations are highlighted to provide an up-to-date understanding of this emerging field.

scholarly journals Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy

2018 ◽  
Vol 19 (12) ◽  
pp. 3950 ◽  
Author(s):  
Marilina García-Aranda ◽  
Elisabet Pérez-Ruiz ◽  
Maximino Redondo
Keyword(s):  
Cancer Treatment ◽  
World Health ◽  
Apoptosis Resistance ◽  
Hallmarks Of Cancer ◽  
Cancer Treatments ◽  
Over Expression ◽  
Promising Strategy ◽  
Anti Cancer ◽  
Health Organization

Abstract: According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. The identification of novel targets for cancer treatment is an area of intense work that has led Bcl-2 over-expression to be proposed as one of the hallmarks of cancer and Bcl-2 inhibition as a promising strategy for cancer treatment. In this review, we describe the different pathways related to programmed cell death, the role of Bcl-2 family members in apoptosis resistance to anti-cancer treatments, and the potential utility of Bcl-2 inhibitors to overcome resistance to chemo- and immunotherapy.

Mesenchymal stem cells strategies in cancer immunotherapy

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Animal Models ◽  
Cancer Treatment ◽  
Cancer Immunotherapy ◽  
Human Studies ◽  
Research Focus ◽  
Cancer Treatments ◽  
The Future ◽  
New Research

Mesenchymal stem cells (MSCs) have been a new research focus for cancer treatment. Future cancer sufferers will considerably profit from their use in the future. Tumor-directed migratory and integration capacities of MSCs are exceptional, making them potential carriers for the delivery of anticancer medicines, notably cytokines. Their usage in the clinic has lasted around 10 years. The use of mesenchymal stem cells (MSCs) to create successful cancer treatments has been demonstrated in everything from animal models to human studies.

Livelihood vs. Life: The Occupational Well-Being of Women Musician Survivors of Breast Cancer

2012 ◽  
Vol 27 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Sarah Schmalenberger ◽  
Charles E Gessert ◽  
Jean E Giebenhain ◽  
Lisa D Starr
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Treatment ◽  
Body Movement ◽  
Well Being ◽  
Physical Symptoms ◽  
Breast Cancer Treatment ◽  
Upper Body ◽  
Long Term Effects ◽  
Cancer Treatments

The Life and Livelihood Study was designed to describe and understand the experience of women musicians treated for breast cancer. This report focuses on Phase I of the study, a web-based survey that examined subjects’ physical symptoms and side effects following breast cancer treatment. Subjects were recruited nationally, using advertisements in musicians’ publications and presentations at national meetings. Subjects were asked about specific side effects or symptoms they had experienced, their severity and duration, and the effects of symptoms on their capacity to make music. Subjects were also asked what aspect of their breast cancer treatment they associated with each symptom and were invited to provide comments. A total of 321 individuals logged on: 100 met all inclusion criteria. Of these, 90 completed the entire survey. Commonly reported symptoms included fatigue (70%), problems with cognition (53%), limitations in upper body movement (51%), and pain (45%). Many reported that their symptoms were of moderate or greater intensity, and that they persisted for >12 months or were ongoing. The survey documented that many subjects experienced diminished capacity to function as musicians, especially due to pain, limitations in upper body and extremity movement, numbness in the chest and/or arms, contracture/fibrosis, and shortness of breath. These findings are consistent with emerging studies that describe long-term effects of breast cancer treatments. In planning for breast cancer treatment, rehabilitation and survivorship, consideration should be given to how treatment is likely to affect fitness for ongoing professional work.

scholarly journals Impact of Treatments on the Family of Breast, Prostate, Colon and Lung Cancer Patients

2017 ◽  
Vol 6 (1) ◽  
pp. 61
Author(s):  
Philippe Groux ◽  
Sandro Anchisi ◽  
Thomas Szucs
Keyword(s):  
Lung Cancer ◽  
Health Care ◽  
Cancer Treatment ◽  
Health Care Providers ◽  
Private Practice ◽  
Cancer Type ◽  
Care Providers ◽  
Cancer Treatments ◽  
Lung Cancer Patients ◽  
The Family

Objective: Many patients describe travel to cancer treatment as inconvenient and a practical hardship and it may be perceived or experienced as a barrier to treatment. We investigated which impact cancer treatments has on the family of the patients, especially for the most frequent cancer type prostate, breast, colon and lung cancer.The aim was to identify groups of patients with an increased burden for the family.Method: All patients coming in February 2012 for chemotherapy to one of the four centres of the hospital or to the unique private practice were asked to answer a survey. The questionnaire covered items as gender, date of birth, living place, kind of cancer, kind of treatment and questions covering different aspects of the travel: how the patient travelled to the centre, how long the travel lasted, which kind of support was necessary to travel and who provided this support, whether the accompanying person had to absent herself from her workplace, whether the patient lives alone or not and how many journeys to health care providers the patients had in the last month were included in the analysisResults: 298 patients answered to all required questions (73%). 186 came accompanied, a vast majority by a member of the family and one out of four of the accompanying person had to leave the workplace. Help at home is almost exclusively provided by family members. Patients have several journeys to health care providers per month.Conclusions: The type of cancer has an impact on the support needed and must added to the previously published factors as age, gender and distance. The journey to the cancer treatment is not the unique journey to health care providers the patients have and increase the burden for the patient and the family.

scholarly journals Bone Health in Men with Prostate Cancer: Review Article

2019 ◽  
Vol 17 (6) ◽  
pp. 527-537 ◽  
Author(s):  
Salma A M El Badri ◽  
Abdulazeez Salawu ◽  
Janet E Brown
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Bone Health ◽  
Cancer Survival ◽  
Cancer Treatments ◽  
Cumulative Impact ◽  
Cancer Review ◽  
Published Evidence ◽  
Prostate Cancer Treatments ◽  
The Impact

Abstract Purpose of Review The improvement in prostate cancer survival over time, even in those with advanced disease, has led to an increasing recognition of the impact of prostate cancer and its treatment on bone health. Cancer treatment–induced bone loss (CTIBL) is a well-recognized entity but greater awareness of the risks associated with CTIBL and its treatment is required. Recent Findings The principal culprit in causing CTIBL is hormonal ablation induced by prostate cancer treatment, including several new agents which have been developed in recent years which significantly improve survival, but may cause CTIBL. This review discusses the impact of prostate cancer and its treatment on bone health, including published evidence on the underlying pathophysiology, assessment of bone health, and strategies for prevention and treatment. Summary It is important to recognize the potential cumulative impact of systemic prostate cancer treatments on bone health.

scholarly journals Improving Access to Cancer Treatments: The Role of Biosimilars

2017 ◽  
Vol 3 (5) ◽  
pp. 596-610 ◽  
Author(s):  
Rakesh Chopra ◽  
Gilberto Lopes
Keyword(s):  
Health Care ◽  
Cancer Treatment ◽  
Health Care Providers ◽  
Cost Effective ◽  
Cancer Therapies ◽  
Care Providers ◽  
Cancer Treatments ◽  
Reference Drug ◽  
Effective Use ◽  
The Cost

Biologics play a key role in cancer treatment and are principal components of many therapeutic regimens. However, they require complex manufacturing processes, resulting in high cost and occasional shortages in supply. The cost of biologics limits accessibility of cancer treatment for many patients. Effective and affordable cancer therapies are needed globally, more so in developing countries, where health care resources can be limited. Biosimilars, which have biologic activity comparable to their corresponding reference drugs and are often more cost effective, have the potential to enhance treatment accessibility for patients and provide alternatives for decision makers (ie, prescribers, regulators, payers, policymakers, and drug developers). Impending patent expirations of several oncology biologics have opened up a vista for the development of corresponding biosimilars. Several countries have implemented abbreviated pathways for approval of biosimilars; however, challenges to their effective use persist. Some of these include designing appropriate clinical trials for assessing biosimilarity, extrapolation of indications, immunogenicity, interchangeability with the reference drug, lack of awareness and possibly acceptance among health care providers, and potential political barriers. In this review, we discuss the potential role and impact of biosimilars in oncology and the challenges related to their adoption and use. We also review the safety and efficacy of some of the widely used biosimilars in oncology and other therapeutic areas (eg, bevacizumab, darbepoetin, filgrastim, rituximab, and trastuzumab).

Sign in / Sign up

Export Citation Format

Share Document